Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors

BACKGROUND: Futibatinib is an oral, irreversible, highly selective fibroblast growth factor receptor (FGFR)1–4 inhibitor with potent preclinical activity against tumors harboring FGFR aberrations. This first-in-human, phase I dose-escalation trial (NCT02052778) evaluates the safety and pharmacokinet...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahleda, R., Meric-Bernstam, F., Goyal, L., Tran, B., He, Y., Yamamiya, I., Benhadji, K. A., Matos, I., Arkenau, H.-T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743148/
https://www.ncbi.nlm.nih.gov/pubmed/32622884
http://dx.doi.org/10.1016/j.annonc.2020.06.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743148/
https://www.ncbi.nlm.nih.gov/pubmed/32622884
http://dx.doi.org/10.1016/j.annonc.2020.06.018

Ejemplares similares